Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/43188
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKapoor, R-
dc.contributor.authorSTANDAERT, Baudouin-
dc.contributor.authorPezalla, EJ-
dc.contributor.authorDemarteau, N-
dc.contributor.authorSutton, K-
dc.contributor.authorTichy, E-
dc.contributor.authorBungey, G-
dc.contributor.authorArnetorp, S-
dc.contributor.authorBergenheim, K-
dc.contributor.authorDarroch-Thompson, D-
dc.contributor.authorMeeraus, W-
dc.contributor.authorOkumura, LM-
dc.contributor.authorYokota, RTD-
dc.contributor.authorGani, R-
dc.contributor.authorNolan, T-
dc.date.accessioned2024-06-18T07:34:15Z-
dc.date.available2024-06-18T07:34:15Z-
dc.date.issued2023-
dc.date.submitted2024-06-18T07:09:39Z-
dc.identifier.citationVaccines (Basel), 11 (2) (Art N° 377)-
dc.identifier.urihttp://hdl.handle.net/1942/43188-
dc.description.abstractHealthcare decision-makers face difficult decisions regarding COVID-19 booster selection given limited budgets and the need to maximize healthcare gain. A constrained optimization (CO) model was developed to identify booster allocation strategies that minimize bed-days by varying the proportion of the eligible population receiving different boosters, stratified by age, and given limited healthcare expenditure. Three booster options were included: B1, costing US $1 per dose, B2, costing US $2, and no booster (NB), costing US $0. B1 and B2 were assumed to be 55%/75% effective against mild/moderate COVID-19, respectively, and 90% effective against severe/critical COVID-19. Healthcare expenditure was limited to US$2.10 per person; the minimum expected expense using B1, B2, or NB for all. Brazil was the base-case country. The model demonstrated that B1 for those aged <70 years and B2 for those ≥70 years were optimal for minimizing bed-days. Compared with NB, bed-days were reduced by 75%, hospital admissions by 68%, and intensive care unit admissions by 90%. Total costs were reduced by 60% with medical resource use reduced by 81%. This illustrates that the CO model can be used by healthcare decision-makers to implement vaccine booster allocation strategies that provide the best healthcare outcomes in a broad range of contexts.-
dc.description.sponsorshipFunding: This research was funded by AstraZeneca. Acknowledgments: We would like to thank Kawthar Nakayima from Evidera Inc., Bethesda, MD, USA for support in preparing this manuscript, which was funded by AstraZeneca. Additional medical writing support for this manuscript, which was in accordance with Good Publication Practice 2022 (GPP 2022) guidelines and funded by AstraZeneca, was provided by Stacey Human, and Christopher Spencer, of Parexel International-
dc.language.isoen-
dc.rights2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms andconditions of the Creative CommonsAttribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).-
dc.subject.otherCOVID-19 vaccination-
dc.subject.otherbooster-
dc.subject.otherconstrained optimization model-
dc.subject.otherbudget constraint-
dc.subject.otherbooster allocation-
dc.subject.otherbudget and healthcare resources-
dc.titleIdentification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget-
dc.typeJournal Contribution-
dc.identifier.issue2-
dc.identifier.volume11-
local.bibliographicCitation.jcatA1-
local.type.refereedRefereed-
local.type.specifiedArticle-
local.bibliographicCitation.artnr377-
dc.identifier.doi10.3390/vaccines11020377-
dc.identifier.pmid36851254-
dc.identifier.isi000942046800001-
local.provider.typeWeb of Science-
local.uhasselt.internationalyes-
item.fullcitationKapoor, R; STANDAERT, Baudouin; Pezalla, EJ; Demarteau, N; Sutton, K; Tichy, E; Bungey, G; Arnetorp, S; Bergenheim, K; Darroch-Thompson, D; Meeraus, W; Okumura, LM; Yokota, RTD; Gani, R & Nolan, T (2023) Identification of an Optimal COVID-19 Booster Allocation Strategy to Minimize Hospital Bed-Days with a Fixed Healthcare Budget. In: Vaccines (Basel), 11 (2) (Art N° 377).-
item.contributorKapoor, R-
item.contributorSTANDAERT, Baudouin-
item.contributorPezalla, EJ-
item.contributorDemarteau, N-
item.contributorSutton, K-
item.contributorTichy, E-
item.contributorBungey, G-
item.contributorArnetorp, S-
item.contributorBergenheim, K-
item.contributorDarroch-Thompson, D-
item.contributorMeeraus, W-
item.contributorOkumura, LM-
item.contributorYokota, RTD-
item.contributorGani, R-
item.contributorNolan, T-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
crisitem.journal.issn2076-393X-
crisitem.journal.eissn2076-393X-
Appears in Collections:Research publications
Show simple item record

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.